Consistent with Sun's report, our results showed that phospho‐VEGFR2, phospho‐AKT, and phospho‐ERK1/2 expression levels were downregulated in HUVECs treatment in a conditioned medium from SPRY4‐IT1‐silenced glioma cells, which significantly weakened HUVECs proliferation and migration viability. The gene discussed is MAPK3; the disease is glioma.